查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1830987

呼吸道感染治療市場

Respiratory Tract Infection Treatment Market
出版日期: | 出版商: The Insight Partners | 英文 150 Pages | 商品交期: 1-5個工作天內

價格
簡介目錄

呼吸道感染治療市場預計將從 2024 年的 440.9 億美元成長到 2031 年的 691.3 億美元，預計 2025 年至 2031 年期間的複合年成長率為 5.93%。呼吸道感染 (RTI) 會影響鼻竇、喉嚨、呼吸道或肺部。全球呼吸道感染治療市場報告強調了推動市場成長的主要因素，並概述了主要參與者的進展。成長動力包括全球呼吸道感染發病率的上升、對 RTI 及其治療的認知的提高以及越來越多的針對 RTI 療法的臨床試驗。然而，對呼吸療法的研究有限以及與 RTI 藥物相關的副作用對市場擴張構成了挑戰。此外，預計抗病毒治療的出現將在不久的將來為全球呼吸道感染治療市場帶來新的趨勢。

成長動力與限制因素：老年人呼吸系統疾病診斷需求不斷成長隨著全球老年人口的成長，預計未來幾年呼吸系統疾病診斷需求將持續成長。例如，2021年11月發表在《英國藥理學雜誌》上的一項研究指出，英國每年約有1%的人口被診斷出患有社區獲得性肺炎 (CAP)，其中約70%發生在65歲以上的人群中，該人群的30天死亡率約為20%。因此，人口老化和CAP等疾病發病率的上升可能會推動呼吸系統疾病治療的需求，從而促進整體市場成長。

該領域的持續研發催生了各種診斷測試和程序，預計將在未來幾年對市場成長產生積極影響。創新診斷技術可望在預測期內為市場擴張帶來巨大機會。然而，呼吸道感染藥物相關的研究不足和不良反應可能會限制全球呼吸道感染治療市場的成長。

策略洞察市場細分與範圍：透過研究以下細分市場對全球呼吸道感染治療市場進行分析：藥物類型、疾病適應症、給藥途徑、年齡層和配銷通路。市場依藥物分為抗生素、非類固醇抗發炎藥、止咳藥、鼻減充血劑等。依疾病適應症分為上呼吸道感染和下呼吸道感染。給藥途徑分為口服和非注射。年齡層細分包括兒科和成人類別。最後，分銷管道分為醫院藥房、網路藥房和零售藥房。

細分分析：就藥物類型而言，抗生素細分市場在2023年佔據了全球呼吸道感染治療市場的最大佔有率，預計在2023年至2031年期間將呈現最高的複合年成長率。呼吸道感染（RTI）包括支氣管炎、肺炎和鼻竇炎等各種疾病，通常由細菌病原體引起。抗生素能夠有效靶向並消除這些有害細菌，減輕炎症，並促進患者更快康復。常用的呼吸道感染處方抗生素包括青黴素、頭孢菌素、大環內酯類、氟喹諾酮類和四環素類，每種抗生素的作用機轉和針對的細菌標靶各不相同。

就疾病適應症而言，下呼吸道感染細分市場在2023年佔據了更大的市場佔有率，預計2023年至2031年期間的複合年成長率將更高。下呼吸道感染 (LRTI) 會影響肺部和支氣管，通常由細菌、病毒或真菌病原體引起。肺炎、支氣管炎和細支氣管炎等疾病的症狀包括咳嗽咳痰、胸部不適、呼吸急促和發燒，均屬於 LRTI 範疇。肺炎是 LRTI 的一種嚴重形式，涉及肺組織發炎和感染，導致肺實變和氣體交換受損。

按給藥途徑分類，口服藥物在全球呼吸道感染治療市場中佔據主導地位，預計在2023年至2031年期間將實現更高的複合年成長率。口服抗生素，例如阿莫西林、阿奇黴素和強力黴素，通常用於治療導致呼吸道感染的細菌性病原體。此外，口服皮質類固醇可用於緩解重症氣喘或慢性阻塞性肺病 (COPD) 急性發作期的發炎。奧司他韋等口服抗病毒藥物也用於治療流感等病毒性呼吸道感染。口服途徑具有給藥方便、患者依從性高及藥物全身分佈等優點。

從年齡層來看，2023年成人呼吸道感染治療市場在全球呼吸道感染治療市場中佔據較大佔有率，而兒科市場預計在2023年至2031年間將呈現更高的複合年成長率。人們越來越意識到早期診斷和治療兒童呼吸道感染的重要性，以及呼吸設備的進步，這些因素正在推動新的、更有效的治療方案的發展。此外，對預防性醫療保健的日益重視也促進了兒科市場的成長。

在分銷管道方面，預計醫院藥房將在2023年至2031年期間佔據顯著的市場佔有率。醫院藥局是醫療保健系統的重要組成部分，尤其在治療需要靜脈或肌肉注射藥物的急性和嚴重呼吸道感染方面發揮重要作用。這些藥局負責購買、儲存和調配抗生素、抗病毒藥物、皮質類固醇和其他呼吸道感染治療藥物，確保這些藥物安全及時地送達醫院內的住院和門診病患。

呼吸道感染治療市場報告範圍區域分析：人們越來越意識到早期診斷和治療呼吸道感染的重要性，這可能會推動未來幾年全球呼吸道感染治療市場的成長。市場細分為北美、歐洲、亞太、中東和非洲以及南美和中美。 2023 年，北美佔據全球呼吸道感染治療市場的最大佔有率，由於該地區呼吸道感染的高發病率，該地區經歷了顯著成長。造成呼吸道感染發生率高的因素包括空氣污染、吸菸和擁擠的生活條件。呼吸道感染盛行率的上升、醫療保健意識的提高以及政府的有利舉措正在推動全球呼吸道感染治療市場的成長。

競爭格局與關鍵參與者：全球呼吸道感染治療市場的預測可以幫助利害關係人規劃其成長策略。全球呼吸道感染治療市場報告中介紹的主要參與者包括雅培實驗室、阿斯特捷利康公司、Alembic Pharmaceuticals Ltd.、勃林格殷格翰國際有限公司、葛蘭素史克公司、梯瓦製藥工業有限公司、諾華公司、羅氏公司、賽諾菲公司、默克公司和西普拉。這些公司採用各種策略（有機和無機）來滿足不斷成長的消費者需求，並擴大其專業產品組合中的產品供應。這些公司採用的主要策略包括推出新技術、開發現有產品和擴展地域範圍。

目錄

第1章：簡介

第2章：執行摘要

  • 關鍵見解
  • 市場吸引力分析

第3章：研究方法

第4章：呼吸道感染治療市場格局

  • 概述
  • PEST分析

第5章：呼吸道感染治療市場－關鍵市場動態

  • 關鍵市場促進因素
  • 主要市場限制因素
  • 關鍵市場機會
  • 未來趨勢
  • 促進因素和限制因素的影響分析

第6章：呼吸道感染治療市場-全球市場分析

  • 呼吸道感染治療－全球市場概覽
  • 呼吸道感染治療－全球市場及2031年預測

第7章：呼吸道感染治療市場－收入分析－依藥物分類，2021-2031

  • 概述
  • 抗生素
  • 非類固醇抗發炎藥（NSAIDS）
  • 止咳藥
  • 鼻減充血劑
  • 其他

第8章：呼吸道感染治療市場-收入分析-按疾病適應症，2021-2031

  • 概述
  • 上呼吸道感染
  • 下呼吸道感染

第9章：呼吸道感染治療市場-收入分析-按配銷通路，2021-2031

  • 概述
  • 醫院藥房
  • 零售藥局
  • 網路藥局

第 10 章：呼吸道感染治療市場 - 收入分析，2021-2031 - 地理分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 英國
    • 歐洲其他地區
  • 亞太
    • 澳洲
    • 中國
    • 印度
    • 日本
    • 韓國
    • 亞太其他地區
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 中東和非洲其他地區
  • 南美洲和中美洲
    • 巴西
    • 阿根廷
    • 南美洲和中美洲其他地區

第 11 章：產業格局

  • 併購
  • 協議、合作、合資企業
  • 新產品發布
  • 擴張和其他策略發展

第 12 章：競爭格局

  • 關鍵參與者的熱圖分析
  • 公司定位與集中度

第13章：呼吸道感染治療市場－主要公司簡介

  • Abbott
  • AstraZeneca
  • Merck and Co
  • Boehringer Ingelheim International GmbH
  • GlaxoSmithKline plc
  • Teva Pharmaceutical Industries Ltd
  • Cipla
  • Novartis AG
  • F. Hoffmann La Roche Ltd
  • Sanofi

第 14 章：附錄

簡介目錄
Product Code: TIPRE00003835

The respiratory tract infection treatment market is projected to grow from US$ 44.09 billion in 2024 to US$ 69.13 billion by 2031, with an expected CAGR of 5.93% during the period from 2025 to 2031.Respiratory tract infections (RTIs) affect the sinuses, throat, airways, or lungs. The global market report for respiratory tract infection treatment highlights the main factors propelling market growth and outlines the advancements made by key players. The growth drivers include the increasing global incidence of respiratory infections, heightened awareness regarding RTIs and their treatments, and a growing number of clinical trials focused on RTI therapies. However, limited research on respiratory therapeutics and the side effects associated with RTI medications pose challenges to market expansion. Additionally, the emergence of antiviral treatments is anticipated to introduce new trends in the global respiratory tract infection treatment market in the near future.

Growth Drivers and Restraints:Increasing Demand for Respiratory Disease Diagnosis in the Elderly

With the global elderly population on the rise, the demand for diagnosing respiratory diseases is expected to grow in the upcoming years. For example, a study published in the British Journal of Pharmacology in November 2021 noted that approximately 1% of the UK population is diagnosed with community-acquired pneumonia (CAP) each year, with around 70% of these cases occurring in individuals over 65 years old, and a 30-day mortality rate of about 20% in this demographic. Therefore, the aging population and the increasing incidence of conditions like CAP are likely to drive demand for respiratory disease treatments, thereby enhancing overall market growth.

Ongoing research and development in this area have led to the creation of various diagnostic tests and procedures that are expected to positively influence market growth in the coming years. Innovative diagnostic techniques are likely to provide significant opportunities for market expansion during the forecast period. However, the lack of research studies and adverse reactions associated with respiratory infection medications may limit the growth of the global respiratory tract infection treatment market.

Strategic Insights

Market Segmentation and Scope:The analysis of the global respiratory tract infection treatment market has been conducted by examining the following segments: drug type, disease indication, route of administration, age group, and distribution channel. The market is categorized by drugs into antibiotics, NSAIDs, cough suppressants, nasal decongestants, and others. By disease indication, it is divided into upper respiratory tract infections and lower respiratory tract infections. The route of administration is classified into oral and parenteral. The age group segmentation includes pediatric and adult categories. Lastly, the distribution channels are segmented into hospital pharmacies, online pharmacies, and retail pharmacies.

Segment Analysis:In terms of drug type, the antibiotics segment accounted for the largest share of the global respiratory tract infection treatment market in 2023 and is expected to exhibit the highest CAGR from 2023 to 2031. RTIs include various conditions such as bronchitis, pneumonia, and sinusitis, often caused by bacterial pathogens. Antibiotics are effective in targeting and eliminating these harmful bacteria, reducing inflammation, and facilitating quicker recovery. Commonly prescribed antibiotics for RTIs include penicillins, cephalosporins, macrolides, fluoroquinolones, and tetracyclines, each with distinct mechanisms of action and bacterial targets.

Regarding disease indication, the lower respiratory tract infection segment held a larger market share in 2023 and is projected to experience a higher CAGR from 2023 to 2031. Lower respiratory tract infections (LRTIs) affect the lungs and bronchial tubes and are typically caused by bacterial, viral, or fungal pathogens. Conditions such as pneumonia, bronchitis, and bronchiolitis, which present symptoms like productive cough, chest discomfort, shortness of breath, and fever, fall under the LRTI category. Pneumonia, a severe form of LRTI, involves inflammation and infection of lung tissue, leading to pulmonary consolidation and impaired gas exchange.

By route of administration, the oral segment dominated the global respiratory tract infection treatment market and is expected to register a higher CAGR during 2023 to 2031. Oral antibiotics such as amoxicillin, azithromycin, and doxycycline are commonly prescribed to treat bacterial pathogens responsible for RTIs. Additionally, oral corticosteroids may be used to alleviate inflammation in severe asthma or chronic obstructive pulmonary disease (COPD) exacerbations. Oral antiviral medications like oseltamivir are also utilized for treating viral respiratory infections such as influenza. The oral route offers advantages such as ease of administration, patient compliance, and systemic drug distribution.

In terms of age group, the adult segment held a larger share of the global respiratory tract infection treatment market in 2023, while the pediatric segment is expected to show a higher CAGR from 2023 to 2031. Factors such as increased awareness of the importance of early diagnosis and treatment of respiratory infections in children, along with advancements in respiratory devices, are leading to the development of new and more effective treatment options. Furthermore, the growing emphasis on preventive healthcare is contributing to the market growth for the pediatric segment.

Regarding distribution channels, the hospital pharmacies segment is expected to capture a significant market share from 2023 to 2031. Hospital pharmacies are crucial components of healthcare systems, particularly in managing acute and severe respiratory tract infections that require intravenous or intramuscular medication administration. These pharmacies are responsible for sourcing, storing, and dispensing antibiotics, antivirals, corticosteroids, and other treatments for respiratory infections, ensuring their safe and timely delivery to both inpatient and outpatient settings within hospitals.

Scope of the Respiratory Tract Infection Treatment Market Report

Regional Analysis:Growing awareness among the population regarding the significance of early diagnosis and treatment of respiratory infections is likely to drive the global respiratory tract infection treatment market growth in the coming years. The market is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa, and South and Central America. North America held the largest share of the global respiratory tract infection treatment market in 2023, experiencing significant growth due to the high prevalence of respiratory tract infections in the region. Contributing factors include air pollution, smoking, and crowded living conditions, which lead to a high incidence of respiratory infections. The increase in respiratory infection prevalence, heightened healthcare awareness, and favorable government initiatives are propelling the growth of the global respiratory tract infection treatment market.

Competitive Landscape and Key Players:The forecast for the global respiratory tract infection treatment market can assist stakeholders in planning their growth strategies. Key players profiled in the global respiratory tract infection treatment market report include Abbott Laboratories, AstraZeneca plc, Alembic Pharmaceuticals Ltd., Boehringer Ingelheim International GmbH, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd, Novartis AG, F. Hoffmann-La Roche AG, Sanofi S.A., Merck & Co., and Cipla. These companies employ various strategies (both organic and inorganic) to meet the growing consumer demand and expand their product offerings in specialized portfolios. Major strategies adopted by these companies include launching new technologies, developing existing products, and expanding geographically.

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 Market Definition, Assumptions and Limitations
  • 1.3 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights
  • 2.2 Market Attractiveness Analysis

3. Research Methodology

4. Respiratory Tract Infection Treatment Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis

5. Respiratory Tract Infection Treatment Market - Key Market Dynamics

  • 5.1 Key Market Drivers
  • 5.2 Key Market Restraints
  • 5.3 Key Market Opportunities
  • 5.4 Future Trends
  • 5.5 Impact Analysis of Drivers and Restraints

6. Respiratory Tract Infection Treatment Market - Global Market Analysis

  • 6.1 Respiratory Tract Infection Treatment - Global Market Overview
  • 6.2 Respiratory Tract Infection Treatment - Global Market and Forecast to 2031

7. Respiratory Tract Infection Treatment Market - Revenue Analysis (USD Million) - By Drug, 2021-2031

  • 7.1 Overview
  • 7.2 Antibiotics
  • 7.3 Non-Steroidal Anti-Inflammatory Drug (NSAIDS)
  • 7.4 Cough Suppressant
  • 7.5 Nasal Decongestant
  • 7.6 Others

8. Respiratory Tract Infection Treatment Market - Revenue Analysis (USD Million) - By Disease Indication, 2021-2031

  • 8.1 Overview
  • 8.2 Upper Respiratory Tract Infection
  • 8.3 Lower Respiratory Tract Infection

9. Respiratory Tract Infection Treatment Market - Revenue Analysis (USD Million) - By Distribution Channel, 2021-2031

  • 9.1 Overview
  • 9.2 Hospital Pharmacies
  • 9.3 Retail Pharmacies
  • 9.4 Online Pharmacies

10. Respiratory Tract Infection Treatment Market - Revenue Analysis (USD Million), 2021-2031 - Geographical Analysis

  • 10.1 North America
    • 10.1.1 North America Respiratory Tract Infection Treatment Market Overview
    • 10.1.2 North America Respiratory Tract Infection Treatment Market Revenue and Forecasts to 2031
    • 10.1.3 North America Respiratory Tract Infection Treatment Market Revenue and Forecasts and Analysis - By Drug
    • 10.1.4 North America Respiratory Tract Infection Treatment Market Revenue and Forecasts and Analysis - By Disease Indication
    • 10.1.5 North America Respiratory Tract Infection Treatment Market Revenue and Forecasts and Analysis - By Distribution Channel
    • 10.1.6 North America Respiratory Tract Infection Treatment Market Revenue and Forecasts and Analysis - By Countries
      • 10.1.6.1 United States Respiratory Tract Infection Treatment Market
        • 10.1.6.1.1 United States Respiratory Tract Infection Treatment Market, by Drug
        • 10.1.6.1.2 United States Respiratory Tract Infection Treatment Market, by Disease Indication
        • 10.1.6.1.3 United States Respiratory Tract Infection Treatment Market, by Distribution Channel
      • 10.1.6.2 Canada Respiratory Tract Infection Treatment Market
        • 10.1.6.2.1 Canada Respiratory Tract Infection Treatment Market, by Drug
        • 10.1.6.2.2 Canada Respiratory Tract Infection Treatment Market, by Disease Indication
        • 10.1.6.2.3 Canada Respiratory Tract Infection Treatment Market, by Distribution Channel
      • 10.1.6.3 Mexico Respiratory Tract Infection Treatment Market
        • 10.1.6.3.1 Mexico Respiratory Tract Infection Treatment Market, by Drug
        • 10.1.6.3.2 Mexico Respiratory Tract Infection Treatment Market, by Disease Indication
        • 10.1.6.3.3 Mexico Respiratory Tract Infection Treatment Market, by Distribution Channel
  • 10.2 Europe
    • 10.2.1 Germany
    • 10.2.2 France
    • 10.2.3 Italy
    • 10.2.4 Spain
    • 10.2.5 United Kingdom
    • 10.2.6 Rest of Europe
  • 10.3 Asia-Pacific
    • 10.3.1 Australia
    • 10.3.2 China
    • 10.3.3 India
    • 10.3.4 Japan
    • 10.3.5 South Korea
    • 10.3.6 Rest of Asia-Pacific
  • 10.4 Middle East and Africa
    • 10.4.1 South Africa
    • 10.4.2 Saudi Arabia
    • 10.4.3 U.A.E
    • 10.4.4 Rest of Middle East and Africa
  • 10.5 South and Central America
    • 10.5.1 Brazil
    • 10.5.2 Argentina
    • 10.5.3 Rest of South and Central America

11. Industry Landscape

  • 11.1 Mergers and Acquisitions
  • 11.2 Agreements, Collaborations, Joint Ventures
  • 11.3 New Product Launches
  • 11.4 Expansions and Other Strategic Developments

12. Competitive Landscape

  • 12.1 Heat Map Analysis by Key Players
  • 12.2 Company Positioning and Concentration

13. Respiratory Tract Infection Treatment Market - Key Company Profiles

  • 13.1 Abbott
    • 13.1.1 Key Facts
    • 13.1.2 Business Description
    • 13.1.3 Products and Services
    • 13.1.4 Financial Overview
    • 13.1.5 SWOT Analysis
    • 13.1.6 Key Developments
  • 13.2 AstraZeneca
  • 13.3 Merck and Co
  • 13.4 Boehringer Ingelheim International GmbH
  • 13.5 GlaxoSmithKline plc
  • 13.6 Teva Pharmaceutical Industries Ltd
  • 13.7 Cipla
  • 13.8 Novartis AG
  • 13.9 F. Hoffmann La Roche Ltd
  • 13.10 Sanofi

14. Appendix

  • 14.1 Glossary
  • 14.2 About The Insight Partners
  • 14.3 Market Intelligence Cloud